Knight Therapeutics Inc. experiences slight fluctuations in its stock performance this week.
Knight Therapeutics Inc. (GUD.TO) saw a modest increase of 0.32% over the past week, while today's trading reflects a decline of 2.21%, closing at C$9.21. The stock's performance remains noteworthy as it continues to gain attention from investors amidst recent company news.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeAdvertisement
Market cap
$933.20M
P/E
63.3x
52W high
$10.17
52W low
$5.66
1W change
+0.32%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 16.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$10.83
+16.6% Upside
Current Price
C$9.29
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
29.5%
Annualized
90-Day Vol
31.7%
Annualized
Trend (90d)
+40.8%
Annualized drift
90d Mean
C$10.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.75 | C$8.81 – C$10.80 |
| 60 trading days | C$10.24 | C$8.87 – C$11.82 |
| 90 trading days | C$10.75 | C$9.01 – C$12.82 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Despite the slight dip today, Knight Therapeutics has demonstrated strong year-to-date performance, with a 57.19% increase. Investors should remain aware of upcoming earnings calls and the overall market sentiment surrounding the biotech sector.
Knight Therapeutics' stock is currently trading at C$9.21.
The stock has a 52-week range of C$5.66 to C$10.17, indicating it is currently 79% of the way through its yearly range.
Bull case
Knight Therapeutics has made impressive gains this year, and with an average analyst target of C$10.83, there’s potential for further growth. The company’s focus on specialty pharmaceuticals positions it well in the expanding healthcare market.
Bear case
However, the current profit margin of 2.7% and a P/E ratio of 63.33 may raise concerns about profitability and valuation. Additionally, the recent decline in share price could indicate potential volatility ahead.
Recent Price Action
Advertisement
Knight Therapeutics Inc. (GUD.TO) has seen a slight increase of 0.32% over the past week, but today's trading resulted in a decline of 2.21%, closing at C$9.21. This fluctuation highlights the stock's volatility as it navigates investor sentiment.
Company News
Recently, Knight Therapeutics announced a conference call scheduled for July 30, 2026, to discuss its second-quarter results. This announcement may attract investor attention as the company prepares to share insights into its financial performance and future outlook.
Technical Picture
Currently, Knight Therapeutics is trading below its 50-day moving average of C$9.49, which is a decline of 2.9%. However, it remains well above its 200-day moving average of C$7.32, reflecting a 25.9% increase. The stock's 52-week range of C$5.66 to C$10.17 indicates it is currently 79% of the way through its yearly range. With a beta of 0.05, the stock shows low volatility compared to the market, and today's trading volume of 51,669 shares is 1.31 times the 20-day average volume of 92,249 shares.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
